Eli Lilly & Novo Nordisk Reach U.S. Deal to Cut Obesity‑Drug Prices, Unlock Medicare & Medicaid Access
Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) announced a historic agreement with the...
Hot targets
Eli Lilly Announces Phase 3 ATTAIN‑PAD Trial for Oral GLP‑1 Agent orforglipron
Eli Lilly (NYSE: LLY), a global biopharma titan, will commence the ATTAIN‑PAD phase 3 study—an ambitious,...
Lepu’s Minwei Licenses MWN105 Injection to Denmark’s Sidera Bio, Up to $1.01 B in Milestones
Lepu (Beijing) Medical Technology Co., Ltd. (SHE: 300003) announced that its wholly‑owned subsidiary Shanghai Minwei...
CSPC Pharmaceutical Group Announces NMPA Acceptance of Efmedaglutide Alfa Injection for Long‑Term Weight Management
CSPC Pharmaceutical Group Limited (HKG: 1093) today announced that the National Medical Products Administration (NMPA)...
PegBio Signs Non‑Binding Term Sheet with UAE‑Based PDC for Exclusive Middle East & Africa License of Visepegenatide
PegBio Co., Ltd. (HKG: 2565) announced today that it has entered into a non‑binding term...
Eli Lilly to Invest $1B in India, Launch New Hyderabad Manufacturing Hub
Eli Lilly & Co. (NYSE: LLY) has announced a commitment to invest more than USD 1 billion...
Eli Lilly’s Orforglipron Outperforms Oral Semaglutide in ACHIEVE‑3 Phase 3 Trial
Eli Lilly and Company (NYSE: LLY) announced positive topline results from the open‑label, randomized Phase 3...